Discontinuation of imatinib therapy after achieving a molecular response.

Adult Aged Antineoplastic Agents/therapeutic use Benzamides Female Fusion Proteins, bcr-abl/metabolism Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy,genetics,therapy Male Piperazines/therapeutic use Polymerase Chain Reaction Pyrimidines/therapeutic use Remission Induction Time Factors Treatment Outcome

Antineoplastic Agents Benzamides Piperazines Pyrimidines Imatinib Mesylate Fusion Proteins, bcr-abl